Full-Time
Data/AI Product Owner Senior Manager
International Commercial
Gilead Sciences
10,001+ employees
Biopharmaceutical firm developing HIV/AIDS therapies
No salary listed
Uxbridge, UK
In Person
 Product (2) |
|---|
| , |
- Bachelor’s degree with extensive years of relevant experience or Master’s degree with extensive years of relevant experience in product management, analytics, data, or related disciplines.
- Deep understanding of commercial processes
- Demonstrated experience as a Product Owner or Product Manager, with a strong track record of translating business needs into scalable data and AI solutions.
- Strong stakeholder management and influence skills, including the ability to operate as a trusted advisor to senior Commercial leaders.
- Demonstrated business and financial acumen with the ability to evaluate ROI, cost-to-value trade-offs and long-term platform investments.
- Solid understanding of data and AI architecture concepts, with the ability to discuss design options and trade‑offs with engineering and data science teams.
- Familiarity with SAP and modern data platforms such as Databricks and AWS.
- Proven experience working in Agile/Scrum environments, using metrics‑driven approaches to guide prioritization and delivery.
- Ability to operate with minimal direction, exercising sound judgment, initiative, and accountability consistent with an Associate Director‑level individual contributor role.
- Own the end‑to‑end product vision and multi‑year roadmap for a portfolio of AI-enabled capabilities for commercial use cases, balancing enterprise priorities, platform constraints and value realization.
- Partner with Business to identify pain points, define high‑value AI and advanced analytics opportunities, and develop compelling business cases.
- Translate business objectives into clear product requirements and backlog items, incorporating data architecture, platform constraints, and scalability considerations.
- Prioritize the product backlog based on business value, risk, technical feasibility, and alignment with enterprise data and AI strategy.
- Identify gaps between current‑state capabilities and target‑state solutions, influencing Databricks, AWS, and data platform evolution in partnership with technical leaders.
- Define and track success metrics such as cost reduction, productivity gains, user adoption, and satisfaction; use insights to guide continuous improvement.
- Drive change management and user adoption, including designing for user experience, stakeholder communications, training strategies, and feedback loops.
- Facilitate working sessions and design workshops with Commercial stakeholders, data scientists, engineers, and architects to align on solution design and trade‑offs.
- Own the vendor and partner strategy for product support, including external development capacity and AI/LLM capabilities, in coordination with IT and Procurement.
- Serve as a trusted advisor to Commercial leadership, applying strong business and financial acumen to evaluate trade‑offs and recommend data‑ and AI‑driven solutions.
Gilead Sciences discovers, develops, and markets medicines to treat HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions. Its products reach patients globally after regulatory approval, sold through doctors, hospitals, and pharmacies. The company relies on a large, diverse R&D pipeline and strategic partnerships to expand its therapies and reach, including collaborations like SAP Ariba to improve sourcing. Its goal is to improve health equity by expanding access to medicines and promoting sustainable healthcare practices worldwide.
Company Size
10,001+
Company Stage
IPO
Headquarters
Foster City, California
Founded
1987
Simplify's Take
What believers are saying
- Twice-yearly lenacapavir can expand HIV prevention adoption through better adherence.
- South Africa’s rollout validates a scalable access model in high-burden markets.
- Islatravir/lenacapavir topline results create a weekly HIV treatment extension opportunity.
What critics are saying
- Generic licensing limits lenacapavir pricing power in low-income markets.
- Biktarvy concentration exposes revenue to pricing pressure and regimen switching.
- Acquisition charges and debt issuance keep near-term earnings under pressure.
What makes Gilead Sciences unique
- Gilead leads with HIV prevention and treatment, anchored by lenacapavir and Biktarvy.
- It operates across virology, oncology, liver disease, and inflammatory therapeutics.
- Its licensing network spans 120 low- and lower-middle-income countries for lenacapavir.
Help us improve and share your feedback! Did you find this helpful?
Your Connections
People at Gilead Sciences who can refer or advise you
Benefits
Paid family time off and paid parental time off
Generous 401(k) contribution matching
Comprehensive medical plans that cover both physical and mental healthcare
Global Wellbeing Reimbursement
Time Off
Global Volunteer Day
Giving Together Program
Employee Support Programs
Flexible Work Options
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 0%Staggering results show hiv-transmission reduced 100% with twice-yearly Lenacapavir injection. Jun 9, 2026 A 2-stage trial testing a new and acclaimed HIV-prevention drug has shown almost unthinkable results of no new infections among a sample size of 3,200 participants. Called PURPOSE 1, the aim of the first trial was testing a subcutaneous injection of the drug Lenacapavir given twice a year to people in a high-HIV-incidence country, which in this case was Uganda or South Africa. The results were nothing short of extraordinary - 100% efficacy, not a single young woman contracted HIV. This was followed up by PURPOSE 2, which expanded the geographical area significantly to more countries on more continents, and expanded the pool of individuals from beyond just young women to men - and to those of all ages. 5,000 participants took part. The result was the same: 99.9% reduction in infection rates. Both were considered phase 3 clinical trials, and were conducted in a randomized, double-blinded protocol, but were not tested against a placebo. Instead, the Lenacapavir injections were compared to the current standard of HIV prevention - a pill called Truvada or Descovy taken daily. These both were also found to prevent HIV transmission by 99.9% during development, but must be taken every day to achieve this level of protection. As anyone who's tried to stick to a once-a-day pill regime long-term will agree, it's not an easy thing to maintain month after month. By contrast, the twice-yearly injections are much easier to adhere to, and they also come with the added benefit of removing the social stigma of being seen taking a daily pill and therefore at risk of HIV transmission. This can be particularly alleviating in high-HIV-prevalent countries where male homosexuality is illegal, such as Uganda. Indeed the superiority of a twice-yearly injection was so clear that both PURPOSE trials were halted early over ethical reasons. A 52-week follow-up screened for HIV developments. Lenacapavir was named by Science Magazine as the Breakthrough of the Year in 2024, and was approved by the FDA for use in humans under the brand name Yeztugo. It works to break down the HIVs capsid shell by binding to an "highly conserved" protein on the exterior. That means that no matter how many times or into what form the virus mutates, the exterior shell protein remains - presenting the perfect target for the drug. In layman's terms, the drug then works through the protein to disrupt the capsid shell, which the virus 'takes down' and 'builds up' several times during its lifecycle with perfect geometric precision. The disruption prevents the virus from completing its life cycle. Initial R&D, regulation compliance, and proof of efficacy and safety requirements mean that producing Lenacapavir has cost its developer, Gilead Sciences, an undisclosed total cost that would be reasonable to estimate at well over a billion dollars based on normal pharma development costs. Gilead has nevertheless committed to providing the drug at cost in certain low-income regions and has licensed generic manufacturers to produce it for approximately $40 per year in 120 low and middle-income countries starting in 2027.
Tempus AI expands oncology data collaboration with Gilead Sciences through AI-driven platform access. April 10, 2026 Tempus AI, Inc. (Nasdaq: TEM), a Chicago-based technology company, announced an expanded multi-year collaboration with Gilead Sciences, Inc. (Nasdaq: GILD) aimed at advancing Gilead's oncology pipeline through enterprise-wide access to Tempus's AI-driven Lens platform and multimodal real-world evidence datasets. The agreement covers multiple oncology indications; no specific drug candidates or therapeutic targets were disclosed as part of the transaction. Financial terms were not disclosed. Under the expanded arrangement, Gilead gains enterprise-wide access to the Tempus Lens platform, which integrates de-identified genomic, clinical, imaging, and outcomes data into a unified repository supported by AI-driven analytical tooling. Disclosed applications include trial design, indication selection, biomarker strategy, health outcomes analysis, and clinical real-world evidence generation. Tempus will also provide dedicated analytical services under the agreement. The collaboration represents an expansion of a pre-existing relationship in which Gilead had previously used Tempus data to inform oncology R&D initiatives, and follows on from a collaboration between Tempus and Daiichi Sankyo announced in March 2026. The collaboration is designed to operate across Gilead's oncology pipeline rather than in support of a single program. Gilead's oncology portfolio includes sacituzumab govitecan, axicabtagene ciloleucel, brexucabtagene autoleucel, and magrolimab, among other assets, though none were named as specific beneficiaries of the arrangement. The platform's stated functions - indication prioritization, patient stratification, biomarker pre-validation, and real-world evidence generation - are applicable across tumor types and development stages. Your email address will not be published. Required fields are marked *
Kymera Therapeutics will receive a $45 million milestone payment following Gilead Sciences' decision to exercise its option to exclusively licence KT-200, a first-in-class oral CDK2 molecular glue degrader development candidate. Gilead will advance the programme into IND-enabling studies, targeting an IND filing in 2027. KT-200 is expected to become the first molecular glue discovered by Kymera to enter clinical trials. The drug candidate demonstrated low-nanomolar degradation of CDK2 in preclinical testing, with robust activity in cancer cell lines and favourable safety profiles. It targets cancers driven by CCNE1 amplification, including advanced breast cancer. Under their collaboration agreement, Kymera is eligible for up to $750 million in total payments and has received $85 million to date. The company will also receive tiered royalties on net product sales.
Gilead to acquire Tubulis for up to $5B, expanding cancer ADC capabilities. April 7, 2026 Gilead Sciences has agreed to acquire German-based Tubulis for up to $5 billion, the companies said today, in a deal designed to expand the buyer's antibody-drug conjugate (ADC) capabilities with a focus on fighting cancer. Headquartered in Munich, privately held Tubulis has developed next-generation ADC candidates based on its own conjugation, linker and payload technologies intended to more selectively deliver diverse payloads to tumors deemed to be of high unmet need. The companies said Tubulis' programs and platforms have broad potential across multiple tumor types, complementing Gilead's development and commercialization expertise in oncology. "We like the strategic fit and deal terms of the Tubulis (private) acquisition," Daina M. Graybosch, PhD, senior managing director, immuno-oncology and a senior research analyst at Leerink Partners, wrote this morning in a research note. "This is more than an oncology bolt-on; we see real platform value in application of Tubulis' ADC technologies to other therapeutic areas, namely virology." Tubulis' lead pipeline candidate, TUB-040, is a sodium-dependent phosphate transport protein 2B (NaPi2b)-targeting topoisomerase-I inhibitor (TOPO1i) ADC that is now under study in the Phase Ib/II NAPISTAR1-01 trial (NCT06303505) assessing its safety, pharmacokinetics, and preliminary efficacy as a treatment for platinum-resistant ovarian cancer and non-small cell lung cancer (NSCLC). In October at the European Society for Medical Oncology (ESMO), Graybosch noted, Tubulis presented data for TUB-040 showing a confirmed 50% overall response rate (ORR) and a 60% unconfirmed ORR across dose levels and irrespective of target antigen - results that were competitive with more mature datasets from leading TOPO1i ADCs. "Though the dataset was early, and our primary outgoing question was how durability would mature, we suspect that Gilead saw durability maturing positively in their diligence," Graybosch added. "If TUB-040 proves active in NSCLC, the program could complement their Trodelvy and IO [immune-oncology] lung programs. We wonder if Gilead saw early clinical NSCLC data in their diligence and if excitement around the emerging signal drove some of Tubulis' valuation." Another Tubulis pipeline candidate, TUB-030, is a 5T4-targeting ADC that according to the companies has shown promising initial clinical data across various solid tumor types. TUB-030 is currently under study in the Phase I/IIa 5-STAR 1-01 trial (NCT06657222), a first-in-human study which aims to evaluate the safety, tolerability, pharmacokinetics, and efficacy of TUB-030 as a monotherapy in patients with advanced solid tumors. Tubulis has said it is developing TUB-030 for up to 13 undisclosed solid tumor indications. Partners since 2024. The acquisition deal follows a two-year, up-to-$465 million collaboration with Tubulis launched in December 2024. Gilead gained access to Tubulis' Tubutecan and Alco5 platforms after signing an exclusive option and license agreement to discover and develop an ADC against a solid tumor target. At the time, Gilead agreed to pay Tubulis $20 million upfront, received an option that if exercised would have given Tubulis an additional $30 million - plus up to $415 million in payments tied to achieving development and commercialization milestones, as well as mid-single to low double-digit tiered royalties on sales of marketed products resulting from the collaboration. "Today's agreement follows a two-year collaboration with Tubulis, which has given us strong conviction in their programs and research capabilities," Gilead Chairman and CEO Daniel O'Day said in a statement. "The agreement to acquire Tubulis is a significant milestone in Gilead's progress in oncology. The company brings a clinical-stage candidate that is a potential new treatment for ovarian cancer, as well as a next-generation ADC platform and a promising early pipeline." "Bringing this potential into Gilead would further expand what is already the strongest and most diverse pipeline in our company's history," O'Day declared. Investors appeared less enthusiastic about the acquisition, as shares of Gilead dipped 1.7% in early Tuesday trading to $137.80 as of 12:01 p.m. ET. Tubulis is Gilead's third announced acquisition this year. The biotech giant announced plans in March to buy Ouro Medicines for up to $2.18 billion, and in February agreed to acquire Arcellx for up to $7.8 billion - for which it agreed last week to extend its tender offer until 5 p.m. ET on April 24. Under the acquisition deal, Gilead agreed to acquire all of the outstanding equity of Tubulis for $3.15 billion in upfront cash payable at closing, and up to $1.85 billion in payments tied to milestones. The transaction is expected to close in the second quarter subject to expiration or termination of specified regulatory filings and other customary conditions. Upon closing of the deal, Tubulis will operate as a dedicated ADC research organization within Gilead, with the Munich site serving as a hub for ADC innovation, building on its integrated discovery, manufacturing, and clinical capabilities to advance next generation ADCs. Gilead said it plans to finance the transaction with a combination of cash on hand and senior unsecured notes. Gilead finished 2025 with $10.605 billion of cash, cash equivalents and marketable debt securities, up from $9.991 billion as of December 31, 2024.
Gilead Sciences, biopharmaceutical company that discovers, develops, manufactures and commercializes therapies for critical diseases. Here you'll find information about their funding, investors and team.